Applied BioCode's EUA permits the pooled testing of up to five individual specimens from patients suspected of having COVID-19. The BioCode SARS CoV-2 Assay is run on the automated BioCode MDx-3000 Molecular System.
With "pooled sampling" the system can test 2,820 samples per day.
The FDA is authorizing pooled-sample testing as more efficient than individual testing, meaning that fewer testing supplies are used and more tests can be run at the same time and in most cases, this allows patients to receive their test results more quickly.
Pooled testing is most efficient in areas with low prevalence, meaning most results are expected to be negative.
As a condition of authorization Applied BioCode has agreed to conduct additional pooled sample testing at three different clinical sites.
The BioCode SARS-CoV-2 Assay is designed to provide accurate results by detecting two different regions of the SARS-CoV-2 virus N gene.
The assay can be run as an independent assay or in parallel with our FDA-cleared BioCode Respiratory Pathogen Panel for a more complete respiratory infection profile of patients.
Applied BioCode is an IVD manufacturer that designs, develops, and commercializes multiplex testing products.
The company has combined "digital barcodes" with immuno- and molecular chemistry to create a new, bio-inspired Barcoded Magnetic Beads technology.
The micro BMBs, about the diameter of a human hair, are tagged with immunochemistry or molecular probes, allowing the digital barcodes to be easily scanned and accurately identified up to 4,096 barcodes with no ambiguity for biological targets.
The company is FDA-510K cleared for their Respiratory 17-plex Pathogen Panel and Gastrointestinal 17-plex Pathogen Panel based on their BioCode MDx-3000 automated system.
Applied BioCode also partners with a variety of diagnostic companies with applications that include the infectious disease, autoimmune disease, allergy, gut microbiome, and veterinary markets.
This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b) (1) of the Act, 21. USC. § 360bbb3(b) (1), unless the authorization is terminated or revoked sooner.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial